Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: A placebo-controlled trial

Journal of Clinical Psychiatry

Volumn 65, Issue 4, 2004, Pages 565-568

  Bystritsky, Alexander ^a,c   Ackerman, Deborah L ^b   Rosen, Richard M ^a   Vapnik, Tanya ^a   Gorbis, Eda ^a   Maidment, Karron M ^a   Saxena, Sanjaya ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; OBSESSIVE COMPULSIVE DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 2442562322     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0418     Document Type: Article

References (23)

1. McDougle CJ, Goodman WK, Price LH. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry 1993:26(suppl 1):24-29 (Pubitemid 23193095)
2. McDougle CJ, Goodman WK, Price LH, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1995;51:302-308
3. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801 (Pubitemid 30650116)
4. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408
5. Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-145 (Pubitemid 30386882)
6. Marazzitti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder [letter]. Am J Psychiatry 1999;156:1834-1835 (Pubitemid 29517585)
7. Weiss EL, Potenza MN, McDougle CJ, et al. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999;60:524-527 (Pubitemid 29413472)
8. Koran LM, Ringold AL, Elliot MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000;61:514-517 (Pubitemid 30483423)
9. Bogette F, Bellino S, Vaschetto P, et al. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96:91-98 (Pubitemid 30785840)
10. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
11. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 2: validity. Arch Gen Psychiatry 1989;46:1012-1016
12. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-388. Rockville, Md: National Institute of Mental Health; 1976:218-222
13. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33 (Pubitemid 29001829)
14. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Psychol 1967;6:278-296
15. Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, eds. Long-Term Treatments of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996:285-309
16. Hamilton M. A rating scale for anxiety. J Neurol Neurosurg Psychiatry 1960;23:56-62
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988
18. Shapira NA, Ward HE, Mandoki M, et al. Placebo-controlled trial of fluoxetine vs fluoxetine plus olanzapine in OCD [poster]. Presented at the 41st annual meeting of the American College of Neuropsychopharmacology; December 8-12, 2002; San Juan, Puerto Rico
19. Hertel P, Nomikos GG, Schilstrom B, et al. Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of alpha-2 adrenoreceptor antagonism. Neuropsychopharmacol 1997;17:44-55 (Pubitemid 27259712)
20. Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treatment resistant major depression. Am J Psychiatry 2001;158:131-134 (Pubitemid 32047260)
21. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429
22. Dominguez RA, Mestre SM. Management of treatment-refractory obsessive compulsive disorder patients. J Clin Psychiatry 1994;55(suppl 10):86-92
23. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122 (Pubitemid 27149253)